As you all know, I will be stepping down today after 5 deeply rewarding years as President and CEO of Teva. When I joined Teva, the company was already a generics powerhouse, with annual revenues of over $8 billion. The growth strategy we have implemented over these last 5 years has turned Teva into a larger, highly diversified global pharmaceutical company. As CEO, it has been extremely gratifying to lead Teva through this exciting period in its history. At a personal level, it has been a true privilege to work with Teva outstanding management team and employees to create a stronger and more balanced Teva.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon